Cencora stock: Barclays raises price target to 415 dollars
Published on 11/19/2026 at 12:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points for investors
- Barclays kept its Overweight rating on Cencora after reviewing the company's initial fiscal 2027 outlook.
- The analyst sees room for Cencora's valuation discount to drug-distribution peers to narrow.
Barclays raised its price target for Cencora on Wednesday, November 18, while maintaining an Overweight rating on the shares. Markets Insider reported that Barclays analyst Glen Santangelo lifted the target from 350 to 415 US dollars.
Barclays raises valuation target
Barclays left its Overweight view unchanged and described Cencora's initial fiscal 2027 outlook as reasonable. The analyst said Cencora had underperformed drug distributors year to date and traded at a 16 percent discount to the peer group.
Barclays expects that discount to narrow if the company's fundamentals remain broadly positive across its businesses. The assessment adds an analyst perspective to Cencora's transition into fiscal 2027, following its fiscal fourth-quarter results and changes to its reporting structure.
Cencora stock traded at 317.90 euros on Lang & Schwarz at 12:39 CET on Thursday, November 19.
Cencora Inc.
- ISIN: US03073E1055
- Ticker: COR
- Lang & Schwarz quote: 317.90 euros, Thursday, November 19, 2026, 12:39 CET
Cencora's latest reported fiscal year ended September 30, 2026. The company reported fiscal fourth-quarter revenue of 88.4 billion US dollars and adjusted diluted earnings per share of 4.66 US dollars on November 4. Its fiscal 2027 outlook calls for adjusted diluted earnings per share of 19.40 to 19.75 US dollars and revenue growth of 3 to 5 percent.
The company is also reorganizing its reporting structure around pharmaceutical distribution and specialty services. Cencora has said the new structure is intended to improve visibility and focus as specialty pharmaceuticals, provider services and distribution remain central to its growth plans.
The relevant broad-market benchmark for Cencora's primary US listing is the S&P 500.
Further company-specific developments can be followed through More news and analyses on Cencora stock.
